The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Translational Cancer Research

Our task is to understand the basic mechanisms behind tumor development. This understanding provides a basis for matching the right drug with the right patient and thereby offer better conditions for individualized treatment of cancer patients.

The Division of Translational Cancer Research (TCR) was founded 2013 in conjunction with the formation of Lund University Cancer Center (LUCC) at Medicon Village. TCR consists of twelve research groups with different areas of expertise, but together working on projects with the common goal of improving cancer diagnostics and cancer therapy. Our multidisciplinary experimental settings include human genetics, mouse genetics, human tissue platform, stem cell biology and advanced imaging, aiming at creating novel diagnostic tools and therapeutic modalities. We believe that the impact of ongoing projects at TCR will open up new horizons and opportunities for individualized treatment of cancer patients, which includes diagnostic tests for matching the right drug to the right patient.

Picture of the Spark building at Medicon Village.
Medicon Village. Photo: Anders Tidén
Image of PI Alexander Pietras standing in the lab area.

Division head

PI Alexander Pietras

Phone: +46 46 222 64 31
Mail: alexander [dot] pietras [at] med [dot] lu [dot] se

Site manager

Research admin Johanna Verngren

Phone: +46 46 222 64 32
johanna [dot] verngren [at] med [dot] lu [dot] se